Almotriptan: meeting today’s needs in acute migraine treatment

References

• Lipton RB, Bigal ME, Diamond M et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J. Headache Pain6, 429–440 (2005).
   PubMedGoogle Scholar
• Santanello NC, Davies G, Allen C, Kramer M, Lipton R. Determinants of migraine-specific quality of life. Cephalalgia22, 680–685 (2002).
   PubMed Web of Science ®Google Scholar
• Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J. Headache Pain6, 429–440 (2005).
   PubMedGoogle Scholar
• Goldberg LD. The cost of migraine and its treatment. Am. J. Manag. Care11(Suppl. 2), S62–S67 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations. How to match patients and products. CNS Drugs17, 431–447 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55, 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Lipton RB. Disability assessment as a basis for stratified care. Cephalalgia18(Suppl. 22), 40–43 (1998).
   PubMed Web of Science ®Google Scholar
• Lucas C. Strategies to improve migraine treatment results. Drugs66(Suppl. 3), 9–16 (2006).
   Google Scholar
• Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract.6, 698–706 (2006).
   Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol.55, 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaulation survey. Headache43, 19–26 (2003).
   PubMed Web of Science ®Google Scholar
• Pascual J, Leira R, Láinez JM et al. Spanish study of quality of life in migraine (II). Profile of medication consumption and subjective efficacy. Neurologia14, 204–209 (1999).
   PubMedGoogle Scholar
• Mateos V, Díaz-Insa SI, Morera J, Porta J, Pascual J, Matías-Guiu J. PALM Program Scientific Commitee. Migraine managing in neurological consults in Spain: PALM program results. Neurologia3(Suppl.), 7–14 (2007).
   Google Scholar
• Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM. Almotriptan, a new anti-migraine agent: a review. CNS Drugs8, 217–234 (2002).
   Google Scholar
• McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine. Clin. Pharmacokinet.44, 237–246 (2005).
   PubMed Web of Science ®Google Scholar
• McEwen J, Salvà M, Jansat JM, Cabarrocas X. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. Biopharm. Drug Dispos.25, 303–311 (2004).
   PubMed Web of Science ®Google Scholar
• Pascual J, Munoz P. Correlation between lipophilicity and triptan outcomes. Headache45, 3–6 (2005).
   PubMed Web of Science ®Google Scholar
• Salvà M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab. Dispos.31, 404–411 (2003).
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology57, 1811–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Cabarrocas X, Salvà M, Pavesi M, Costa J. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, Phase I clinical trial in healthy volunteers. Int. J. Clin. Pharmacol. Ther.44, 443–448 (2006).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med.57, 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Maassen van den Brink A, Vergouwe MN, Ophoff RA et al. Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine. Am. J. Med. Genet.5, 415–420 (1998).
   Google Scholar
• Maassen van den Brink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR. 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache38, 288–291 (1998).
   PubMedGoogle Scholar
• Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J. Cardiovasc. Pharmacol.37, 280–289 (2001).
   PubMedGoogle Scholar
• Fleishaker JC, McEnroe JD, Azie NE, Francom SF, Carel BJ. Cardiovascular effect of almotriptan in treated hypertensive patients. Clin. Pharmacol. Ther.71, 169–175 (2002).
   PubMedGoogle Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache41, 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia20, 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum dose comparison. Arch. Neurol.58, 944–950 (2001).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia22, 453–461 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia26, 400–408 (2006).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia20, 765–786 (2000).
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache43, 36–43 (2003).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache42, 21–27 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin. Ther.24, 520–529 (2002).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events end point in clinical trials of triptans in acute migraine. CNS Drugs21, 73–82 (2007).
   PubMed Web of Science ®Google Scholar
• Mathew NT. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache42, 32–40 (2002).
   Web of Science ®Google Scholar
• Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol.45, 206–213 (2001).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia24, 417–424 (2004).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Triptans and chest symptoms: the role of pulmonary vasoconstriction. Cephalalgia24, 298–304 (2004).
   PubMedGoogle Scholar
• Pascual J, Lainez JM, Leria R et al. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologia18, 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Láinez MJA, Pascual J, Mateos V, Galván J. Real world experience comparing neurologist and primary care physician management of acute migraine with almotriptan in Spain. Presented at: the 56th Annual Meeting of the American Academy of Neurology. San Francisco, CA, USA, 24 April–1 May 2004.
   Google Scholar
• Pascual J. Efficacy and tolerability of almotriptan in postmarketing surveillance studies. Eur. Neurol.53(Suppl. 1), 34–40 (2005).
   PubMed Web of Science ®Google Scholar
• Diener H-C. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache45, 624–631 (2005).
   PubMed Web of Science ®Google Scholar
• Massiou H, Pradalier A, Donnet A, Lanteri-Minet M, Allaf B. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. Eur. Neurol.55, 198–203 (2006).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Pascual J et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol. Scand.115, 34–40 (2007).
   PubMed Web of Science ®Google Scholar
• Iglesias Díez F, Straube A, Zanchin G. Patient preference in migraine therapy: a randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J. Neurol.254, 242–249 (2007).
   PubMedGoogle Scholar
• Láinez MJA, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol.14, 269–275 (2007).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache45, 156–162 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans – review of four trials. Cephalalgia26, 98–106 (2005).
   Google Scholar
• Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache45, 874–882 (2005).
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Busssone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci.27(Suppl. 2), S193–S197 (2006).
   PubMed Web of Science ®Google Scholar
• Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs19, 951–972 (2005).
   PubMed Web of Science ®Google Scholar
• Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs20, 1019–1026 (2006).
   PubMed Web of Science ®Google Scholar
• Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin. Ther.27, 1785–1794 (2005).
   PubMed Web of Science ®Google Scholar
• Mannix LK, Loder E, Nett R et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomizes, placebo-controlled, double-blind studies. Cephalalgia27, 414–421 (2007).
   PubMed Web of Science ®Google Scholar
• Massiou H, Jamin C, Hinzelin G et al. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur. J. Neurol.12, 774–781 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon S, Frishberg B, Hu XH, Markson L, Berger M. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study. Clin. Ther.23, 886–900 (2001).
   PubMed Web of Science ®Google Scholar
• Martin VT, Valade D, Almas M et al. Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. Headache47, 181–118 (2007).
   PubMedGoogle Scholar
• Goadsby PJ, Vila C. ‘ACT’ when mild: early versus non-early almotriptan intervention in migraine. Cephalalgia26, 1393–1394 (2006) (Abstract).
   Google Scholar
• Pascual J. Clinical benefits of early triptan therapy for migraine. Headache42(Suppl. 1), S10–S17 (2002).
   PubMedGoogle Scholar
• Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache46(Suppl. 4), S182–S191 (2006).
   Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache42, 28–31 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Early intervention with almotriptan improves pain-free response in acute migraine. Headache43, 1075–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates with treatment is within 1 h of migraine onset. Headache44, 318–322 (2004).
   PubMed Web of Science ®Google Scholar
• Láinez MJA. Clinical benefits of early triptan therapy for migraine. Cephalalgia24(Suppl. 2), 24–30 (2004).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT® 12.5 mg time versus intensity migraine study (AIMS). Headache47, 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache47, 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost–effectiveness in migraine. Pharmacoeconomics23, 259–274 (2005).
   PubMedGoogle Scholar
• Williams P, Reeder CE. Cost–effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin. Ther.25, 2903–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Williams P, Reeder CE. A comparison of the cost–effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm.10, 259–265 (2003).
   Google Scholar
• Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J. Manag. Care Pharm.9, 45–52 (2003).
   PubMedGoogle Scholar
• Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Muri L. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med.97, 467–477 (2006).
   PubMedGoogle Scholar
• Kelman L, von Seggern RL. Using patient-centered end points to determine cost–effectiveness of triptans for acute migraine therapy. Am. J. Ther.13, 411–417 (2006).
   PubMedGoogle Scholar
• Slof J, Badia X, Lainez-Andres JM, Galvan J, Heras J. Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans. Neurologia20, 290–298 (2005).
   PubMedGoogle Scholar
• Lipton RB, Cutrer FM, Goadsby PJ et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr. Med. Res. Opin.3, 413–424 (2005).
   Google Scholar
• Dodick DW, Lipton RB, Ferrari AD et al. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR project. Curr. Pain Headache Rep.8, 435–442 (2004).
   PubMedGoogle Scholar
• Cutrer FM, Goadsby PJ, Ferrari AD et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR project). Clin. Ther.26, 1533–1545 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Liberman J, Cutrer FM et al. Treatment preferences and the selection of acute migraine medications: results from a population-based survey. J. Headache Pain5, 123–130 (2004).
   Google Scholar
• Ferrari MD, Goadsby PJ, Lipton RB et al. The use of multiattribute decision models in evaluating triptan treatment options. J. Neurol.252, 1026–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs19, 769–784 (2005).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. MedGenMed8, 31 (2006).
   PubMedGoogle Scholar